P2, N=20, Recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting --> Recruiting

3 days ago

Enrollment open

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)

KRAS mutation • BRAF mutation • KRAS G12D • BRAF wild-type • KRAS G12

Avastin (bevacizumab) • capecitabine • oxaliplatin

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov)

P1, N=39, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

6 days ago

Trial completion

BRAF (B-raf proto-oncogene)

BRAF wild-type

Opdivo (nivolumab) • Yervoy (ipilimumab) • Stivarga (regorafenib)

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov)

P1/2, N=28, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Aug 2026

6 days ago

Trial completion date

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)

BRAF wild-type

Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)

Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer. (PubMed, Int J Mol Sci)

In external transcriptomic validation (TCGA-CRC), GSEA indicated enrichment of interferon/inflammatory programs in TIGIT-high tumors, while CD155-high tumors preferentially showed proliferation-related MYC/E2F/G2M signatures. Together, these findings support tumor-wide upregulation of the TIGIT/CD155 axis in CRC and suggest that TIGIT, more than CD155, tracks with MSI/BRAF-associated immune activation, providing a rationale for patient stratification in checkpoint-directed immunotherapy.

6 days ago

Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CSF1 (Colony stimulating factor 1) • PVR (PVR Cell Adhesion Molecule) • IL1R1 (Interleukin 1 receptor, type I)

BRAF mutation • PIK3CA mutation • BRAF wild-type • AKT1 mutation

10d

Summary and Analysis of Molecular Biological Changes, PD-L1 Immune Status and Clinicopathological Features of 78 Cases of Papillary Thyroid Carcinoma (<1 cm in Diameter) Combined With Lateral Cervical Lymph Node Metastasis. (PubMed, Appl Immunohistochem Mol Morphol)

Among them, patients with BRAF and K-RAS gene mutations are usually accompanied by positive expression of ER and PR, suggesting that these patients may benefit from endocrine therapy. In addition, PD-L1-mediated immunotherapy has broad application prospects in this tumor, female patients may benefit more, and immunotherapy combined with endocrine therapy is expected to become a good adjuvant treatment option for female cases.

10 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RET (Ret Proto-Oncogene) • TERT (Telomerase Reverse Transcriptase)

PD-L1 expression • KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • HER-2 mutation • BRAF wild-type • RAS mutation • RET mutation

11d

Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes. (PubMed, J Gastroenterol Hepatol)

Nonmetastatic BRAFmut CRC carries a dismal prognosis, irrespective of MMR status. Routine testing for BRAFV600E mutation alongside MMR assessment is advocated to inform personalized management, potentially impacting surveillance, adjuvant therapy decisions, and eligibility for targeted therapies.

11 days ago

Journal

BRAF (B-raf proto-oncogene)

BRAF V600E • MSI-H/dMMR • BRAF mutation • BRAF V600 • BRAF wild-type

11d

A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)

P1/2, N=126, Not yet recruiting, Shanghai Henlius Biotech

11 days ago

New P1/2 trial

BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)

MSI-H/dMMR • BRAF wild-type

Hetronifly (serplulimab) • pimurutamab (HLX07) • HLX43

11d

COLIBRI-GI: Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases (clinicaltrials.gov)

P2, N=130, Not yet recruiting, UNICANCER

11 days ago

New P2 trial • Mismatch repair • pMMR

BRAF (B-raf proto-oncogene)

BRAF wild-type

Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Yidafan (ivonescimab)

12d

Desmoplastic infantile ganglioglioma/astrocytoma: Expanding the molecular and morphological spectrum with a novel BRAF fusion. (PubMed, Neurooncol Adv)

The most common molecular signature of these tumors is BRAF alterations, including rearrangements. The primary differential diagnosis is infant-type hemispheric glioma and given the similarities, pathologists must remain careful to ensure accurate diagnosis.

12 days ago

Journal

BRAF (B-raf proto-oncogene)

BRAF mutation • BRAF V600 • BRAF wild-type • BRAF fusion

17d

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (clinicaltrials.gov)

P=N/A, N=105, Recruiting, AstraZeneca | N=384 --> 105

17 days ago

Enrollment change

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)

MSI-H/dMMR • BRAF mutation • HER-2 expression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type

Enhertu (fam-trastuzumab deruxtecan-nxki)